Foresite Capital Management IV
Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Relay Therapeutics, Nurix Therapeutics, KROS, KURA, Alx Oncology Hldgs, and represent 68.64% of Foresite Capital Management IV's stock portfolio.
- Added to shares of these 8 stocks: Relay Therapeutics (+$91M), Nurix Therapeutics (+$82M), Alx Oncology Hldgs (+$37M), ABUS (+$10M), Therapeutics Acquisition Cor (+$5.0M), Panacea Acquisition Corp, CYTK, ACRS.
- Started 7 new stock positions in Therapeutics Acquisition Cor, Nurix Therapeutics, ABUS, Panacea Acquisition Corp, ACRS, Alx Oncology Hldgs, Relay Therapeutics.
- Reduced shares in these 8 stocks: FULC (-$21M), PCVX (-$7.7M), CBAY (-$7.7M), ORIC, DRNA, RTRX, KROS, GBIO.
- Sold out of its positions in DRNA, FULC, ORIC, RTRX.
- Foresite Capital Management IV was a net buyer of stock by $187M.
- Foresite Capital Management IV has $443M in assets under management (AUM), dropping by 116.02%.
Tip: Access up to 7 years of quarterly data
Positions held by Foresite Capital Management IV, LLC consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Foresite Capital Management IV
Companies in the Foresite Capital Management IV portfolio as of the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Relay Therapeutics | 20.5 | $91M | NEW | 2.1M | 42.59 | |
| Nurix Therapeutics | 18.5 | $82M | NEW | 2.3M | 34.91 | |
| Keros Therapeutics (KROS) | 12.3 | $55M | 1.4M | 38.57 | ||
| Kura Oncology (KURA) | 9.0 | $40M | 1.3M | 30.64 | ||
| Alx Oncology Hldgs | 8.3 | $37M | NEW | 974k | 37.74 | |
| Cytokinetics (CYTK) | 8.2 | $36M | +4% | 1.7M | 21.65 | |
| Generation Bio (GBIO) | 6.0 | $27M | 858k | 30.91 | ||
| Vaxcyte (PCVX) | 5.2 | $23M | -24% | 466k | 49.38 | |
| Myokardia (MYOK) | 3.9 | $17M | 127k | 136.33 | ||
| Cymabay Therapeutics (CBAY) | 2.9 | $13M | -37% | 1.8M | 7.24 | |
| Arbutus Biopharma (ABUS) | 2.4 | $10M | NEW | 3.3M | 3.13 | |
| Voyager Therapeutics (VYGR) | 1.2 | $5.5M | 517k | 10.67 | ||
| Therapeutics Acquisition Corp Com Cl A | 1.1 | $5.0M | NEW | 350k | 14.38 | |
| Panacea Acquisition Corp Unit | 0.4 | $1.8M | NEW | 150k | 12.00 | |
Setup an alertForesite Capital Management IV will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Aclaris Therapeutics (ACRS) | 0.1 | $372k | NEW | 145k | 2.57 | |
Past Filings by Foresite Capital Management IV
SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017
- Foresite Capital Management IV 2020 Q3 filed Nov. 13, 2020
- Foresite Capital Management IV 2020 Q2 filed Aug. 13, 2020
- Foresite Capital Management IV 2020 Q1 restated filed May 28, 2020
- Foresite Capital Management IV 2020 Q1 filed May 14, 2020
- Foresite Capital Management IV 2019 Q4 filed Feb. 14, 2020
- Foresite Capital Management IV 2019 Q3 filed Nov. 13, 2019
- Foresite Capital Management IV 2019 Q2 filed Aug. 13, 2019
- Foresite Capital Management IV 2019 Q1 filed May 14, 2019
- Foresite Capital Management IV 2018 Q4 filed Feb. 13, 2019
- Foresite Capital Management IV 2018 Q3 filed Nov. 13, 2018
- Foresite Capital Management IV 2018 Q2 filed Aug. 14, 2018
- Foresite Capital Management IV 2018 Q1 filed May 15, 2018
- Foresite Capital Management IV 2017 Q4 filed Feb. 13, 2018